661 related articles for article (PubMed ID: 3021967)
21. Conflict and kala-azar: determinants of adverse outcomes of kala-azar among patients in southern Sudan.
Collin S; Davidson R; Ritmeijer K; Keus K; Melaku Y; Kipngetich S; Davies C
Clin Infect Dis; 2004 Mar; 38(5):612-9. PubMed ID: 14986243
[TBL] [Abstract][Full Text] [Related]
22. Epidemiological aspects of kala-azar in Meshkin-Shahr, Iran: human infection.
Soleimanzadeh G; Edrissian GH; Movahhed-Danesh AM; Nadim A
Bull World Health Organ; 1993; 71(6):759-62. PubMed ID: 8313493
[TBL] [Abstract][Full Text] [Related]
23. Risk factors for Indian kala-azar.
Ranjan A; Sur D; Singh VP; Siddique NA; Manna B; Lal CS; Sinha PK; Kishore K; Bhattacharya SK
Am J Trop Med Hyg; 2005 Jul; 73(1):74-8. PubMed ID: 16014837
[TBL] [Abstract][Full Text] [Related]
24. Observations on the effect of verapamil with sodium stibogluconate in kala azar.
Thakur CP; Kumar M
Trop Geogr Med; 1992 Jan; 44(1-2):15-8. PubMed ID: 1323160
[TBL] [Abstract][Full Text] [Related]
25. Asymptomatic infection of visceral leishmaniasis in hyperendemic areas of Vaishali district, Bihar, India: a challenge to kala-azar elimination programmes.
Das VN; Siddiqui NA; Verma RB; Topno RK; Singh D; Das S; Ranjan A; Pandey K; Kumar N; Das P
Trans R Soc Trop Med Hyg; 2011 Nov; 105(11):661-6. PubMed ID: 21945327
[TBL] [Abstract][Full Text] [Related]
26. [Visceral leishmaniasis (Kala-Azar) in a 3-year-old German infant (author's transl)].
Wittermann C; Bienzle U; Betke K
Klin Padiatr; 1979 May; 191(3):311-7. PubMed ID: 222940
[TBL] [Abstract][Full Text] [Related]
27. Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.
Lira R; Sundar S; Makharia A; Kenney R; Gam A; Saraiva E; Sacks D
J Infect Dis; 1999 Aug; 180(2):564-7. PubMed ID: 10395884
[TBL] [Abstract][Full Text] [Related]
28. Problems in the treatment of kala-azar: case report.
Nyakundi PM; Rashid JR; Wasunna KM; Were JB; Muigai R; Kirigi G; Mbugua J
East Afr Med J; 1995 Jun; 72(6):406-8. PubMed ID: 7498017
[TBL] [Abstract][Full Text] [Related]
29. Relevance of direct agglutination test in seroepidemiological survey of Kala-azar in epidemic foci of Bihar.
Sharma MC; Bimal S; Ranjan A; Das VN; Gupta AK; Kumar N; Kar SK
J Commun Dis; 2000 Jun; 32(2):117-22. PubMed ID: 11198396
[TBL] [Abstract][Full Text] [Related]
30. Kala azar--diagnostic dilemma.
Raman TS; Ahuja SA; Mani KV; Jalpota YP; Adaval SK
Indian Pediatr; 1992 Aug; 29(8):1036-9. PubMed ID: 1334051
[No Abstract] [Full Text] [Related]
31. Studies on the vector of kala-azar in Kenya, VIII. The outbreak in Machakos District; epidemiological features and a possible way of control.
Wijers DJ; Kiilu G
Ann Trop Med Parasitol; 1984 Dec; 78(6):597-604. PubMed ID: 6532329
[TBL] [Abstract][Full Text] [Related]
32. Serodiagnosis of Indian kala-azar: evaluation of IFA, ELISA and CIEP tests.
Mittal V; Bhatia R; Sehgal S
J Commun Dis; 1991 Jun; 23(2):131-4. PubMed ID: 1940218
[TBL] [Abstract][Full Text] [Related]
33. Spatial clustering and epidemiological aspects of visceral leishmaniasis in two endemic villages, Baringo District, Kenya.
Ryan JR; Mbui J; Rashid JR; Wasunna MK; Kirigi G; Magiri C; Kinoti D; Ngumbi PM; Martin SK; Odera SO; Hochberg LP; Bautista CT; Chan AS
Am J Trop Med Hyg; 2006 Feb; 74(2):308-17. PubMed ID: 16474089
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.
Singh S; Gilman-Sachs A; Chang KP; Reed SG
J Parasitol; 1995 Dec; 81(6):1000-3. PubMed ID: 8544037
[TBL] [Abstract][Full Text] [Related]
35. A 10 years' study of kala-azar in Tharaka (Meru district, Kenya). II. Relapses.
Wijers DJ
East Afr Med J; 1971 Oct; 48(10):551-8. PubMed ID: 5141410
[No Abstract] [Full Text] [Related]
36. [Kala-azar acquired in Croatia].
Wenzl H; Petritsch W; Decrinis M; Schreiber F; Warnkross H; Pristautz H; Krejs GJ
Wien Klin Wochenschr; 1992; 104(24):757-60. PubMed ID: 1337639
[TBL] [Abstract][Full Text] [Related]
37. [Kala-azar in China from 1985 to 1988. Advisory Committee on Parasitic Diseases, MOPH].
Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 1989; 7(3):161-2. PubMed ID: 2591032
[TBL] [Abstract][Full Text] [Related]
38. Molecular and serological markers of Leishmania donovani infection in healthy individuals from endemic areas of Bihar, India.
Srivastava P; Gidwani K; Picado A; Van der Auwera G; Tiwary P; Ostyn B; Dujardin JC; Boelaert M; Sundar S
Trop Med Int Health; 2013 May; 18(5):548-54. PubMed ID: 23464581
[TBL] [Abstract][Full Text] [Related]
39. Is one year follow-up justified in kala-azar post-treatment?
Nyakundi PM; Wasunna KM; Rashid JR; Gachihi GS; Mbugua J; Kirigi G; Muttunga J
East Afr Med J; 1994 Jul; 71(7):453-9. PubMed ID: 7828500
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a standardized direct agglutination test (DAT) for the diagnosis of visceral leishmaniasis in Kenya.
Mbati PA; Githure JI; Kagai JM; Kirigi G; Kibati F; Wasunna K; Koech DK
Ann Trop Med Parasitol; 1999 Oct; 93(7):703-10. PubMed ID: 10715698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
